Sientra Stock Price, News & Analysis (NASDAQ:SIEN)

$7.17
+0.19 (+2.72 %)
(As of 09/20/2019 04:00 PM ET)
Today's Range
$6.84
Now: $7.17
$7.22
50-Day Range
$4.99
MA: $6.57
$7.12
52-Week Range
$4.78
Now: $7.17
$24.75
Volume599,608 shs
Average Volume758,292 shs
Market Capitalization$353.41 million
P/E RatioN/A
Dividend YieldN/A
Beta0.25
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. Read More…

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SIEN
CUSIPN/A
Phone805-562-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$68.13 million
Book Value$2.34 per share

Profitability

Net Income$-82,630,000.00
Net Margins-151.96%

Miscellaneous

Employees259
Market Cap$353.41 million
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive SIEN News and Ratings via Email

Sign-up to receive the latest news and ratings for SIEN and its competitors with MarketBeat's FREE daily newsletter.


Sientra (NASDAQ:SIEN) Frequently Asked Questions

What is Sientra's stock symbol?

Sientra trades on the NASDAQ under the ticker symbol "SIEN."

How were Sientra's earnings last quarter?

Sientra Inc (NASDAQ:SIEN) released its quarterly earnings results on Thursday, August, 8th. The medical instruments supplier reported ($1.19) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.69) by $0.50. The medical instruments supplier had revenue of $20.53 million for the quarter, compared to analysts' expectations of $19.04 million. Sientra had a negative return on equity of 123.80% and a negative net margin of 151.96%. The business's quarterly revenue was up 17.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.73) EPS. View Sientra's Earnings History.

When is Sientra's next earnings date?

Sientra is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Sientra.

What guidance has Sientra issued on next quarter's earnings?

Sientra issued an update on its FY 2019 earnings guidance on Thursday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $79-83 million, compared to the consensus revenue estimate of $81.13 million.

What price target have analysts set for SIEN?

8 brokerages have issued 12 month price targets for Sientra's shares. Their forecasts range from $10.00 to $27.00. On average, they anticipate Sientra's stock price to reach $15.75 in the next year. This suggests a possible upside of 119.7% from the stock's current price. View Analyst Price Targets for Sientra.

What is the consensus analysts' recommendation for Sientra?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sientra in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sientra.

Has Sientra been receiving favorable news coverage?

Headlines about SIEN stock have been trending negative this week, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Sientra earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned news stories about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Sientra.

Who are some of Sientra's key competitors?

What other stocks do shareholders of Sientra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sientra investors own include Baidu (BIDU), Allergan (AGN), Regions Financial (RF), Verizon Communications (VZ), ChemoCentryx (CCXI), Genocea Biosciences (GNCA), Novavax (NVAX), Alibaba Group (BABA), Oasis Petroleum (OAS) and Idera Pharmaceuticals (IDRA).

Who are Sientra's key executives?

Sientra's management team includes the folowing people:
  • Mr. Jeffrey M. Nugent, Chairman & CEO (Age 72)
  • Mr. Charles Huiner, COO and Sr. VP of Corp. Devel. & Strategy (Age 48)
  • Mr. Keith J. Sullivan, Director & Advisor to MiraDry Bus. (Age 61)
  • Mr. Paul Sean Little, CFO, Sr. VP & Treasurer (Age 54)
  • Ms. Deborah Bettencourt, VP of Customer Experience & Corp. Admin.

Who are Sientra's major shareholders?

Sientra's stock is owned by a variety of of institutional and retail investors. Top institutional investors include UBS Group AG (5.39%), Vanguard Group Inc. (6.36%), BlackRock Inc. (6.08%), Bamco Inc. NY (5.05%), Schroder Investment Management Group (4.28%) and Schroder Investment Management Group (4.28%). Company insiders that own Sientra stock include Jeffrey M Nugent, Keith J Sullivan, Patrick F Williams, Paul Sean Little, R Scott Greer and Timothy Haines. View Institutional Ownership Trends for Sientra.

Which major investors are selling Sientra stock?

SIEN stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Bank of New York Mellon Corp, MUFG Securities EMEA plc, UBS Asset Management Americas Inc., Tower Research Capital LLC TRC , Parametric Portfolio Associates LLC and Morgan Stanley. View Insider Buying and Selling for Sientra.

Which major investors are buying Sientra stock?

SIEN stock was acquired by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Schroder Investment Management Group, UBS Group AG, Vanguard Group Inc., Marshall Wace LLP, Citadel Advisors LLC, AWM Investment Company Inc. and United Services Automobile Association. Company insiders that have bought Sientra stock in the last two years include Jeffrey M Nugent, Keith J Sullivan, Patrick F Williams, Paul Sean Little, R Scott Greer and Timothy Haines. View Insider Buying and Selling for Sientra.

How do I buy shares of Sientra?

Shares of SIEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sientra's stock price today?

One share of SIEN stock can currently be purchased for approximately $7.17.

How big of a company is Sientra?

Sientra has a market capitalization of $353.41 million and generates $68.13 million in revenue each year. The medical instruments supplier earns $-82,630,000.00 in net income (profit) each year or ($3.25) on an earnings per share basis. Sientra employs 259 workers across the globe.View Additional Information About Sientra.

What is Sientra's official website?

The official website for Sientra is http://www.sientra.com/.

How can I contact Sientra?

Sientra's mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The medical instruments supplier can be reached via phone at 805-562-3500 or via email at [email protected]


MarketBeat Community Rating for Sientra (NASDAQ SIEN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  216 (Vote Outperform)
Underperform Votes:  259 (Vote Underperform)
Total Votes:  475
MarketBeat's community ratings are surveys of what our community members think about Sientra and other stocks. Vote "Outperform" if you believe SIEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SIEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel